Acquired ImmPACT Bio and strengthened clinical pipeline with the addition of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate with strong Phase 1 clinical data in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback